Search results
Results from the WOW.Com Content Network
Arena Pharmaceuticals Inc. is an American biopharmaceutical company founded in 1997 and headquartered in San Diego, California. Arena focused on discovering drugs that act on G protein-coupled receptors (GPCRs). The company developed technology it called Constitutively Activated Receptor Technology (CART) that identified drug leads targeting ...
Arena Pharmaceuticals' (NAS: ARNA) obesity drug lorcaserin is currently under review, with a Food and Drug Administration decision expected on or around June 27. Buying in front of such binary ...
Let's look at Arena Pharmaceuticals (NAS: ARNA) today and Examine its pros and cons, and decide whether it's possible upside outweighs its risks. Buy, Sell, or Hold: Arena Pharmaceuticals
Arena Pharmaceuticals (NAS: ARNA) is a clinical-stage biopharmaceutical company focused on developing oral drugs that treat cardiovascular, central nervous system, inflammatory, and metabolic ...
Etrasimod was discovered by Arena Pharmaceuticals, with subsequent development by Pfizer. [10] Etrasimod was approved for medical use in the United States in October 2023, [6] and in the European Union in February 2024. [8]
Olorinab (APD371) is a drug being developed by Arena Pharmaceuticals for the treatment of gastrointestinal pain associated with Crohn's disease and irritable bowel syndrome. [1] It acts as a potent and selective cannabinoid CB 2 receptor agonist and is claimed to be orally active and peripherally selective.
Don't worry, Arena Pharmaceuticals (NAS: ARNA) bulls. This isn't an article designed to bash your beloved obesity-drug maker. There's a more upbeat corollary to this article, "3 Reasons to Buy ...
Lorcaserin, marketed under the brand name Belviq, [4] [5] was a weight-loss drug developed by Arena Pharmaceuticals.It reduces appetite by activating serotonin receptor the 5-HT 2C receptor in the hypothalamus, a region of the brain which is known to control appetite. [6]